<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Research Viral load Surrogate endpoint HIV FDA Fast Track Development Program Clinical endpoint Food and Drug Administration Imaging biomarker Discovery and development of integrase inhibitors Medicine HIV/AIDS Health |
Add to Reading List |
Predicting/Providing Substantial Evidence of Clinical Benefit for New Drug Approvals Albert Deisseroth, Division of Hematology Products February 27, 2013 | June 17, 2009 Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds Damilola A. Adepegba, Department of Natural Sciences, University of MarylandDocID: 1qLnJ - View Document |
 | HIV-1 RT p51 subunit Human Immunodeficiency Virus1 Reverse Transcriptase recombinant, E. coli Cat. No.DocID: O3BG - View Document |
 | HIV-1 RT heterodimer Human Immunodeficiency Virus1 Reverse Transcriptase recombinant, E. coli Cat. No.DocID: NV7P - View Document |
 | AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 106DocID: kfp3 - View Document |
| Predicting/Providing Substantial Evidence of Clinical Benefit for New Drug Approvals Albert Deisseroth, Division of Hematology Products February 27, 2013DocID: ikIg - View Document |